Shire announced an FDA approval for Intuniv (guanfacine) Extended Release Tablets yesterday, and is preparing professional advertising efforts for a November launch. Matthew Cabrey, a spokesperson for ...

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...

INTUNIV is a selective alpha-2A adrenergic receptor agonist. [1] With a unique mechanism of action, INTUNIV represents an additional treatment option in the management of ADHD. "Shire is committed to ...

PHILADELPHIA, Feb. 28, 2011 /PRNewswire/ -- Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) ...

Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...

The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. (The other three are Adderall XR, Vyvanse and the Daytrana patch.) There are about 11 drugs on ...

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results ...

INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...

Teva was looking to launch its generic version of Intuniv and had filed an abbreviated new drug application (ANDA) with the FDA in 2010. Shire subsequently filed a lawsuit against Teva for ...

Shire has been boosted by news that the US Food and Drug Administration has expanded the label on its attention-deficit hyperactivity disorder drug Intuniv. Shire has been boosted by news that the US ...

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV™ (guanfacine) Extended Release Tablets, at a major psychiatric medical ...

Teva Pharmaceutical Industries Ltd is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker's units of illegally delaying the release of a generic ...